> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Baxter Gets EUA for Blood Filter
- URL: https://www.fdaweb.com/baxter-gets-eua-for-blood-filter/
- Published: 2020-04-23T12:00:00.000Z
- Updated: 2026-09-14T16:12:22.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5146644

FDA has granted Baxter International an emergency use authorization for the Oxiris filter set to treat patients who have confirmed Covid-19 and have been admitted to the intensive care unit with confirmed or imminent respiratory failure in need of blood purification therapy to reduce pro-inflammatory cytokine levels, including use in continuous renal replacement therapy. In severe Covid-19 cases, patients may develop acute kidney injury, [according to Baxter](http://www.marketwatch.com/story/baxter-obtains-us-fda-emergency-use-authorization-for-oxiris-blood-purification-filter-for-covid-19-treatment-2020-04-23?ref=fdaweb.com). During blood purification therapy, a patient’s blood passes through the filter set, where it then removes cytokines, endotoxin, fluid and uremic toxins simultaneously, before returning the blood to the body, it says.